Tactile Systems Technology Inc (TCMD) — Titan Protect Analysis

TCMD

Tactile Systems Technology Inc

Healthcare · ·

$25.40

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$544M

Total market value of the company

Trailing P/E

27.71

Premium valuation

Forward P/E

16.02

Based on estimated future earnings — lower means cheaper

Rev Growth

+22.8%

Year-over-year revenue change

Profit Margin

5.9%

How much profit the company keeps from each dollar of revenue

ROE

9.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$40.00

+57% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About Tactile Systems Technology Inc

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds.

https://tactilemedical.com

Country: United States Employees: 1,086 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.908

Good returns relative to risk taken

Kelly Fraction

0.0744

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.859

Acceptable balance between returns and drawdown risk

Annual Return

44.5%

Historical annualised return based on price data

Max Drawdown

-51.8%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.82

Less volatile than the market — more defensive

52W High

$37.77

33% below the year high

52W Low

$9.42

170% above the year low

Avg Volume

305,398

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.87

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

6.97

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

76.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-2.0%

Profit from core operations before interest and tax

Free Cash Flow

$33M

Positive — the business generates more cash than it spends

Revenue (TTM)

$344M

Total revenue over the last 12 months

Net Income

$20M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$42.00

Target Median

$40.00

Target Low

$36.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go